Remdesivir benefit in COVID-19 declines with illness severity, trial finds
The published results of a US government-backed trial show patients needing mechanical ventilation don’t benefit
The benefits of the experimental antiviral remdesivir in cutting time to recovery in patients severely ill with COVID-19 might not extend to those requiring mechanical ventilation, US researchers say.
The highly anticipated preliminary findings from the randomised controlled trial, published in the New England Journal of Medicine on Friday (US local time), also address a controversial decision to change the primary outcome midway through the study.
